Refractory Tumor clinical trials at UCSF

• 9-ING-41 in Pediatric Patients With Refractory Malignancies.

  open to eligible people ages up to 22 years

  9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

  San Francisco, California and other locations

Last updated: March 6, 2021